Daunorubicin HCl

Catalog No.S3035 Synonyms: Daunomycin HCl

Molecular Weight(MW): 563.98

Daunorubicin HCl inhibits both DNA and RNA synthesis and inhibits DNA synthesis with K_i of 0.02 μM in a cell-free assay.

Cited by 25 Publications

Nat Med, 2017, 23(2):250-255

PubMed: 27991919 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2019.224956

PubMed: 31624110 ( click the link to review the publication )

ACS Chem Biol, 2019, 14(3):348-355

PubMed: 30763062 ( click the link to review the publication )

J Lipid Res, 2019, 60(6):1078-1086

PubMed: 30962310 ( click the link to review the publication )

Mol Cancer Res, 2019, 17(12):2457-2468

PubMed: 31551253 ( click the link to review the publication )

J Cell Mol Med, 2019, 23(6):4111-4117

PubMed: 30920135 ( click the link to review the publication )

Int J Biol Sci, 2019, 15(3):579-586

PubMed: 30745844 ( click the link to review the publication )

Oncol Rep, 2019, 41(6):3179-3188

PubMed: 30942458 ( click the link to review the publication )

Oncotarget, 2019, 10(56):5755-5767

PubMed: 31645898 ( click the link to review the publication )

Nat Commun, 2018, 9(1):5378

PubMed: 30568163 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(7):1716-1726

PubMed: 29330206 ( click the link to review the publication )

Bioinformation, 2018, 587-593

PubMed: 31223218 ( click the link to review the publication )

J Exp Clin Cancer Res, 2017, 36(1):22

PubMed: 28143565 ( click the link to review the publication )

Mol Cell Biochem, 2017, 434(1-2):25-32

PubMed: 28397012 ( click the link to review the publication )

Leuk Res, 2017, 63:41-46

PubMed: 29100024 ( click the link to review the publication )

Leuk Res, 2017, 56:36-43

PubMed: 28171800 ( click the link to review the publication )

Sci Transl Med, 2016, 8(339):339ra69

PubMed: 27194727 ( click the link to review the publication )

Toxicol Rep, 2016, 3:430-438

PubMed: 28959565 ( click the link to review the publication )

Toxicology Reports, 2016, 10.1016/j.toxrep.2016.03.008

PubMed: ( click the link to review the publication )

Arch Toxicol, 2016, 90(11):2763-2777

PubMed: 26537877 ( click the link to review the publication )

J Transl Med, 2016, 14(1):132

PubMed: 27176825 ( click the link to review the publication )

Leuk Res, 2015, 39(4):435-44

PubMed: 25659731 ( click the link to review the publication )

J Phys Chem B, 2013, 117(23):6859-67

PubMed: 23692060 ( click the link to review the publication )

J Phys Chem B, 2013, 117(23):6868-73

PubMed: 23692121 ( click the link to review the publication )
J Phys Chem B, 2013, 117(23):6868-73

PubMed: 23692121 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Topoisomerase Inhibitors

Biological Activity

Description

Daunorubicin HCl inhibits both DNA and RNA synthesis and inhibits DNA synthesis with K_i of 0.02 μM in a cell-free assay.

Targets

DNA synthesis ^[1]
(Cell-free assay)

20 nM(Ki)

In vitro

At drug concentrations that reflect the peak plasma concentration after Daunorubicin administration, the primary mechanism is likely to be through interaction with topoisomerase II, which may be a primary triggering event for growth arrest and/or cell killing through a signalling pathway leading to apoptosis, at least in leukemic cells and thymocytes. The quinone structure permits daunorubicin to act as electron acceptors in reactions mediated by oxoreductive enzymes including cytochrome P450 reductase, NADH dehydrogenase, and xanthine oxidase. At Daunorubicin concentrations exceeding approximately 2–4 μM, free radical mediated toxicity and DNA cross-linking may become evident. Daunorubicin inhibits both DNA and RNA syntheses in HeLa cells over a concentration range of 0.2 through 2 μM. Daunorubicin inhibits both DNA syntheses in Ehrlich ascites tumor cells over a concentration range of 4 μM. Daunorubic triggers apoptosis at concentrations of 0.5 and 1 μM in either HL-60 or U-937 human leukemic cells. ^[1] Daunorubicin stimulates ceramide elevation and apoptosis in P388 and U937 cells through de novo synthesis via activation of the enzyme ceramide synthase. ^[2] Daunorubicin dose-dependently increases the phosphatidylserine exposure and consequent procoagulant activity of human umbilical vein endothelial cells. Daunorubicin (0.2 mM) significantly enhances the release of endothelial microparticles which are highly procoagulant in human umbilical vein endothelial cells. ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
P388 leukemia cell line	NXHGUoJMS3m2b4TvfIlkyqCjc4PhfS=>			MojpR49ueG:3bnSge4F{KGW4YXz1ZZRm\CCob4KgZ5l1d3SxeHnjbZR6KGGpYXnud5QhWDN6ODDs[ZVs\W2rYTDj[YxtKGyrbnWsJGlEPTB;MzDuUS=>	MU[xNFQ4QTJ7Nx?=
HL60 cells	NEfmdmZHfW6ldHnvckBie3OjeR?=			NFLKSGlKdiC4aYTyc{BqdmirYnn0c5J6KGOxbnPlcpRz[XSrb36gZYdicW6\|dDDwdo9tcW[ncnH0bY9vKG:oIFjMOlAh[2WubIOsJGlEPTB;MD6wNFUh\|ryP	NX3WT2FEOTJ6N{e1PVM>
human epidermoid carcinoma cell line KB-3-1	Mn60R5l1d3SxeHnjxsBie3OjeR?=			MkTKTY4hfmm2cn:gZ5l1d3SxeHnjJIFkfGm4aYT5JJdieyCndnHseYF1\WRidYPpcochfGinIHj1cYFvKGWyaXTldo1wcWRiY3HyZ4lvd22jIHPlcIwhdGmwZTDLRk0{NTFuIFnDOVA:PyCwTR?=	NEW2N4EyOjR2M{e2Ny=>
human K562 cells	NXjvdFM4S3m2b4TvfIlkyqCjc4PhfS=>		NFGze3c4OiCq	MkLHR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gT\|U3OiClZXzsd{Bi\nSncjC3NkBpenNiYomgXHRVKGG\|c3H5MEBIUTVyPUeuOEBvVQ>?	NHH5bJczODV7MU[3PC=>
Dx5 w/PSC cell lines	M3H0PWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			MYPUbIUh[2:vcH;1coQhf2G\|IHX2ZYx2[XSnZDDmc5IhfGinIHfyc5d1cCCrbnjpZol1cW:wIH;mJGR5PSC5L2DTR{Bk\WyuIHzpcoV{KHW\|aX7nJG1VXCCjc4PhfUwhUUN3ME2xOEBvVQ>?	NFzFOmgyODZ7OES0PS=>
MDA MB 361(mammary carcinoma cell line)	MWPDfZRwfG:6aXRCpIF{e2G7			NYTyNHdiXGinIHPvcZBwfW6mIIfhd{B1\XO2ZXSg[o9zKGmwdILhZ4VtdHWuYYKgZ5l1d3SxeHnjbZR6KGGpYXnud5QhVUSDIF3CJFM3OSivYX3tZZJ6KGOjcnPpco9u[SClZXzsJIxqdmVrIHX4dJJme3OrbnegUIFkYiBqYnX0ZU1o[WyjY4Tvd4ll[XOnKTygTWM2OD1zNzDuUS=>	NFvIO\|YyODN7NUS5NC=>
human MDA-MB-231 cells	M3P1TWN6fG:2b4jpZ:Kh[XO\|YYm=		NYDocHlvPzJiaB?=	MYrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSC\|dXzmc5Jpd2SjbXnu[UBDKGG\|c3H5MEBIUTVyPUCuNFIh\|ryP	NV\iN2pKOTl7NkiyOVg>
MES-SA uterine tumor cell lines	NEjjRWhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			NU\sW5BIXGinIHPvcZBwfW6mIIfhd{BmfmGudXH0[YQh\m:{IITo[UBoem:5dHigbY5pcWKrdHnvckBw\iCPRWOtV2EhfXSncnnu[UB1fW2xcjDj[YxtKGyrbnXzJJV{cW6pIF3UWEBie3OjeTygTWM2OD1yLkCyNUDPxE1?	MV6xNFY6QDR2OR?=
murine L1210 leukemia cells	M3;pVWZ2dmO2aX;uJIF{e2G7			MYjJcohq[mm2b4L5JIFkfGm4aYT5JJdieyCvZXHzeZJm\CCjZ3HpcpN1KG23cnnu[UBNOTJzMDDs[ZVs\W2rYTDj[YxteyxiSVO1NF0{OCCwTR?=	NEDWb4k6PzN\|NEiz
HL60 cells	MU\GeY5kfGmxbjDhd5NigQ>?			M4TldmlvKH[rdILvJINwdmOnboTyZZRqd25icnXxeYlz\WRidH:gbY5lfWOnIHHwc5B1d3OrczDpckBJVDZyIHPlcIx{NCCDQ{WwQVAvODRizszN	NWL2XpR5OTJ6N{e1PVM>
CCRF-CEM (human lymphoblastic leukemic) cells	MWfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			M{\HcWlvKH[rdILvJIdzd3e2aDDpcohq[mm2b4L5JIFkfGm4aYT5JIFo[Wmwc4SgR2NTTi2FRV2gLIh2dWGwIHz5cZBpd2KuYYP0bYMhdGW3a3XtbYMqKGOnbHzzMEBKTDVyPUCuNFQh\|ryP	NXTSSIZLPjl3MUC0PS=>
mouse NIH/3T3 cells	MXvDfZRwfG:6aXRCpIF{e2G7		MlfhO\|IhcA>?	MnrlTY51emmwc3njJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KHerbHSgeJlx\SCvb4Xz[UBPUUhxM2SzJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5yNESg{txO	MVixPFk2PDB2MB?=
human prostate cancer HTB-81 cells	NX;iXJpGS3m2b4TvfIlkyqCjc4PhfS=>			M2fKV2N6fG:2b4jpZ4l1gSC2aHH0JINifXOnZDDhJFUxLSC{ZXT1Z5Rqd25iaX6gZYJ{d3KkYX7j[UBifCB2OUCgco0hcW5iaIXtZY4heHKxc4TheIUh[2GwY3XyJGhVSi16MTDj[YxteyC3c3nu[{BOXFNiYYPzZZktKEWFNUC9NE4xPThizszN	NHPOemgyOTB{MEK4OS=>
human breast carcinoma line cells	MX3GeY5kfGmxbjDhd5NigQ>?			MU\jc41xd3WwZDD3ZZMhfGW\|dHXkJIlvKH[rdILvJIZweiCrbnjpZol1cW:wIHHjeIl3cXS7IHHnZYlve3RiYTDz[Y5{cXSrdnWgbJVu[W5iYoLlZZN1KGOjcnPpco9u[SCuaX7lJINmdGy\|LDDJR\|UxRTBwME[g{txO	M1\qdlkzPTh\|NUG=
MCF-7 cells	MlG2R5l1d3SxeHnjxsBie3OjeR?=			NUD6elYxS2:vcH;1coQhf2G\|IITld5Rm\CCob4KgbZR{KHSxeHnjbZR6KGGpYXnud5QhcHWvYX6gZpJm[XO2IHPhcoNmeiClZXzsd{hOS0ZvNzmsJGlEPTB;MD6wOkDPxE1?	NWXS[pFrQTV2OEiyNC=>
human HT-29 cells	NHfaflFEgXSxdH;4bYPDqGG\|c3H5		NGjlO5Y4OiCq	MkfrR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTHQuOjliY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JJN2dG[xcnjv[IFucW6nIFKgZZN{[XluIFfJOVA:OC5yNzFOwG0>	NWTwdVhzOTl7NkiyOVg>
human uterine sarcoma cell line MES-SA	M3ntTWN6fG:2b4jpZ:Kh[XO\|YYm=			MWfJckB3cXS{bzDjfZRwfG:6aXOgZYN1cX[rdImge4F{KGW4YXz1ZZRm\CC3c3nu[{B1cGViaIXtZY4hfXSncnnu[UB{[XKlb33hJINmdGxibHnu[UBOTVNvU1GsJGlEPTB;MD6wO{DPxE1?	MYexNlQ1Ozd4Mx?=
human MRC5 cells	M3W0OnBzd2yrZnXyZZRqd25iYYPzZZk>			MX\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2UQ{WgZ4VtdHNiYomgXHRVKGG\|c3H5MEBKSzVyPUCuNFc5KM7:TR?=	MV:yOVQ3PzJ7MR?=
MDA435/LCC6 cells	MWXQdo9tcW[ncnH0bY9vKGG\|c3H5			NWfjZWFJSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBOTEF2M{WvUGNEPiClZXzsd{BjgSCHTFnTRUwhUUN3ME2wMlA4QSEQvF2=	MWexO\|E2PDVyNR?=
human A549 cells	NF;EW3hEgXSxdH;4bYPDqGG\|c3H5			NVK5RmpxS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjZoTldkA4OiCqcoOgZpkhe3WuZn;ybI9l[W2rbnWgRkBie3OjeTygS2k2OD1yLkC4JO69VQ>?	NIjnc5gyQTl4OEK1PC=>
Jurkat T lymphocytes	NYPwOHRvS3m2b4TvfIlkyqCjc4PhfS=>			Ml3yR5l1d3SxeHnjbZR6KGGpYXnud5QhUnW{a3H0JHQhdHmvcHjvZ5l1\XNiYomgUXRVKGG\|c3H5MEBKSzVyPUCuNFgzPiEQvF2=	M3K4SlE3OzZ4NkCy
human DU145 cells	MlH3VJJwdGmoZYLheIlwdiCjc4PhfS=>		NEL0PGg4OiCq	NVrXRpBuSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDEWVE1PSClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRUKGG\|c3H5MEBKSzVyPUCuNFkh\|ryP	MWqyNlI3ODF4Nh?=
human MDA-MB-231 cells	MlSwVJJwdGmoZYLheIlwdiCjc4PhfS=>			M1iwSWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVTBMW1DNTJ\|MTDj[YxteyCkeTDYWHQh[XO\|YYmsJGlEPTB;MD6wPVEh\|ryP	MWeyOVQ3PzJ7MR?=
human H1299 cells	NILM[ZNRem:uaX\ldoF1cW:wIHHzd4F6			MV\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEhzMkm5JINmdGy\|IHL5JHhVXCCjc4PhfUwhUUN3ME2wMlA6PiEQvF2=	M17pWlI2PDZ5Mkmx
human HL60 cells	NXW2VJRFS3m2b4TvfIlkyqCjc4PhfS=>		NH;jTXk1QCCq	NFj5O4JEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJVDZyIHPlcIx{KGG\|c3Xzd4VlKGG\|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDR6IHjyd{BjgSC2conwZY4h[my3ZTDzeIFqdmmwZz3iZZNm\CCqZX3vZ5l1d22ndILpZ{BidmGueYPpd{whT0l3ME2wMlEh\|ryP	M1XDSFI2QDd2M{O1
human LNCAP cells	M4jwbWN6fG:2b4jpZ:Kh[XO\|YYm=		M3;BclQh\GG7cx?=	MXXDfZRwe3SjdHnjJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTF7DRXAh[2WubIOgZYZ1\XJiNDDkZZl{KGK7IF3UWEBie3OjeTygTWM2OD1yLkGg{txO	NG\UZZEzOjR6MES5OS=>
NCI-H69 cell line	MWLQdo9tcW[ncnH0bY9vKGG\|c3H5			MnvERY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDkdpVoKHOnboPpeIl3\SCQQ1mtTFY6KGOnbHygcIlv\SCkeTDBcIFu[XJiQnz1[UBie3OjeTygTWM2OD1yLkGg{txO	MYKxO\|I5PjN7Mx?=
human A2780 cells	M2j0XWN6fG:2b4jpZ:Kh[XO\|YYm=		M2XhclczKGh?	NFTGdG1EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCOjd6MDDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvOTF5NEmg{txO	NYfsb3RbOTd6OUCwPVQ>
human HT-29 cells	NF\RcWlRem:uaX\ldoF1cW:wIHHzd4F6		NHj4Zm86PiCq	MYDBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiWLUK5JINmdGy\|IHHmeIVzKDl4IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5zM{Og{txO	NFm4NWczPzd6NES5
B16 mouse melanoma cells	MnXMR5l1d3SxeHnjxsBie3OjeR?=			Mmn4R5l1d3SxeHnjbZR6KHSqYYSgZ4F2e2WmIHGgOVAmKHKnZIXjeIlwdiCrbjDhZpNwemKjbnPlJIF1KDR7MDDucUBqdiCEMU[gcY92e2VibXXsZY5wdWFiY3XscJMhfXOrbnegUXRUKGG\|c3H5MEBGSzVyPUCuNVYh\|ryP	M165U\|EyODJyMki1
human SKMES1 cells	NV3iZ4FFWHKxbHnm[ZJifGmxbjDhd5NigQ>?		NFvV[WE4OiCq	NX\sTWtSSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTT21GWzFiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JG1VWyCjc4PhfUwhUUN3ME2wMlE4KM7:TR?=	M1jleFIzOjZyMU[2
human fibroblast (NHF) cells	NYDlTmdiS3m2b4TvfIlkyqCjc4PhfS=>			MlXxR5l1d3SxeHnjbZR6KHSqYYSgZ4F2e2WmIHGgOVAmKHKnZIXjeIlwdiCrbjDhZpNwemKjbnPlJIF1KDR7MDDucUBqdiCwb4LtZYwhcHWvYX6g[oljem:kbHHzeEApVkiIKTDj[YxteyC3c3nu[{BOXFNiYYPzZZktKEWFNUC9NE4zOiEQvF2=	MoTBNVExOjB{OEW=
mouse L1210 cells	NHG5b\|hHfW6ldHnvckBie3OjeR?=			M{fTRmlvcGmkaYTpc44hd2ZiUl7BJJN6dnSqZYPpd{BqdiCvb4Xz[UBNOTJzMDDj[YxteyxiRVS1NF0xNjJ\|IN88US=>	NIL3cpQ3QTB7OUm=
human NCI-H460 cells	M{LLeGZ2dmO2aX;uJIF{e2G7			NVPBb2JzSW62aXPhcoNmeiCjY4Tpeol1gSCjZ3HpcpN1KGi3bXHuJG5EUS2KNE[wJINmdGy\|LDDJR\|UxRTBwM{ig{txO	MYWyNVU6QTByMB?=
human MCF7 cells	NHfXUHJEgXSxdH;4bYPDqGG\|c3H5		MUm0JIRigXN?	NXzWbXh6S3m2b4P0ZZRq[yCjY4Tpeol1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[W[2ZYKgOEBl[Xm\|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlQh\|ryP	MnTtNlI1QDB2OUW=
human SF268 cells	NHnWfpZHfW6ldHnvckBie3OjeR?=			NXzO[mlrSW62aXPhcoNmeiCjY4Tpeol1gSCjZ3HpcpN1KGi3bXHuJHNHOjZ6IHPlcIx{NCCLQ{WwQVAvPiEQvF2=	MVWyNVU6QTByMB?=
human KB cells	MkH2R5l1d3SxeHnjxsBie3OjeR?=		Mn3ZOFghcA>?	NX7jNGltS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hU0JiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlY1KM7:TR?=	MXeyNFM3OzF2Mh?=
human HepG2 cells	MVjDfZRwfG:6aXRCpIF{e2G7		NF\ZeFUzPCCq	MmjKR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVxTzJiY3XscJMh[W[2ZYKgNlQhcHK\|IHL5JG1VWyCjc4PhfUwhUUN3ME2wMlch\|ryP	MV[yNVA6PDB2OR?=
mouse L5178Y cells	MXnDfZRwfG:6aXRCpIF{e2G7		MW[yOEBp	MnHVR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgUFUyPzi\IHPlcIx{KGGodHXyJFI1KGi{czDifUBOXFRiYYPzZZktKEmFNUC9NE44OiEQvF2=	MUKyN\|E6QTR5OR?=
human MCF7 cells	NHrrXmlEgXSxdH;4bYPDqGG\|c3H5		NFLzTog4OiCq	M3TrUmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JHhVXCCjc4PhfUwhT0l3ME2wMlg3KM7:TR?=	NFTEboIzODV7MU[3PC=>
human MRC5 cells	MYTQdo9tcW[ncnH0bY9vKGG\|c3H5			MVfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2UQ{WgZ4VtdHNuIFnDOVA:OC56ODFOwG0>	NHTwblYzOTV7OUCwNC=>
MDA435/LCC6 cells	M1GwcnBzd2yrZnXyZZRqd25iYYPzZZk>			MkLHRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDteYx1cWS{dXegdoV{cXO2YX70JG1FSTR\|NT;MR2M3KGOnbHzzJIJ6KEWOSWPBMEBKSzVyPUCuPVc4KM7:TR?=	MnO2NVcyPTR3MEW=
mouse NIH/3T3 cells	M4THWmN6fG:2b4jpZ:Kh[XO\|YYm=		MkLyO\|IhcA>?	M{fsPGlvfHKrboPpZ{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBPUUhxM2SzJINmdGy\|IH;2[ZJmgHC{ZYPzbY5oKE2GUkGgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1zLkCxJO69VQ>?	MXGxPFk2PDB2MB?=
human Detroit 551 cells	NIfUd2VEgXSxdH;4bYPDqGG\|c3H5		MojnO\|IhcA>?	NUHjVpZNS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hTGW2cn;peEA2PTFiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JHhVXCCjc4PhfUwhT0l3ME2xMlc4KM7:TR?=	MUWyNFU6OTZ5OB?=
mouse DA-3 cells	NX;i[Yk{S3m2b4TvfIlkyqCjc4PhfS=>		NXPs[IpqOjRiaB?=	MmfSR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgSGEuOyClZXzsd{Bi\nSncjCyOEBpenNiYomgXHRVKGG\|c3H5MEBKSzVyPUGuPUDPxE1?	MkW3NlQ6ODB4Nki=
african green monkey Vero cells	NIToUJREgXSxdH;4bYPDqGG\|c3H5		Mmr1N{Bl[Xm\|	MlnRR5l1d3SxeHnjbZR6KGGpYXnud5Qh[W[{aXPhckBoemWnbjDtc45s\XliVnXyc{Bk\WyuczDh[pRmeiB\|IHThfZMh[nliTWTTJIF{e2G7LDDJR\|UxRTJwNTFOwG0>	MnHYNlExQTRyNEm=
Dx5 cell lines	MUjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			MXzUbIUh[2:vcH;1coQhf2G\|IHX2ZYx2[XSnZDDmc5IhfGinIHfyc5d1cCCrbnjpZol1cW:wIH;mJGR5PSClZXzsJIxqdmW\|IIXzbY5oKE2WVDDhd5NigSxiaXO1NF0zKM7:TR?=	NY\IfGZDOTB4OUi0OFk>
human HeLa3 cell line	MXzDfZRwfG:6aXRCpIF{e2G7			MoDDR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVN[TNiY3XscEBtcW6nIHL5JG1VXCCjc4PhfUwhUUN3ME2yMlk3KM7:TR?=	NFS2UXIyPjl2MkCzOy=>
mouse L5178Y cells	MkP4R5l1d3SxeHnjxsBie3OjeR?=		NV\lXWo{OjRiaB?=	MUnDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDMOVE4QFliY3XscJMh\XiycnXzd4lv\yCyLXfwJIFnfGW{IEK0JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTB;Nz63N{DPxE1?	MmPpNlMyQTl2N{m=
human CRL7761 cells	MnP4R5l1d3SxeHnjxsBie3OjeR?=		MlzuN{Bl[Xm\|	NHK1Vo9EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBEWkx5N{[xJINmdGy\|IHHmeIVzKDNiZHH5d{BjgSCPVGOgZZN{[XluIFnDOVA:OTBwNTFOwG0>	MUWyNVA6PDB2OR?=
human A2780/ADR cells	NF3tT3dEgXSxdH;4bYPDqGG\|c3H5		M1fKdFczKGh?	MlyxR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVI4QDBxQVTSJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OThwNkKwPUDPxE1?	M{nWVlE4QDlyMEm0
human SKOV3 cells	M3OyVmN6fG:2b4jpZ:Kh[XO\|YYm=		MVOyOEBp	NVrIOJFrS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0uRVkOgZ4VtdHNiYX\0[ZIhOjRiaILzJIJ6KFiWVDDhd5NigSxiSVO1NF0zOC54IN88US=>	NUXZdVl6OjR7MEC2Olg>
human ES2 cells	NWCwUm0zS3m2b4TvfIlkyqCjc4PhfS=>		MmLSNlQhcA>?	Mnu4R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gSXMzKGOnbHzzJIFnfGW{IEK0JIhzeyCkeTDYWHQh[XO\|YYmsJGlEPTB;MkWuOUDPxE1?	MlrmNlQ6ODB4Nki=
CEM cells	NHvDU5pEgXSxdH;4bYPDqGG\|c3H5		NInI[5o4OiCq	MYXDfZRwfG:6aXPpeJkh[WejaX7zeEBETU1iY3XscJMh[W[2ZYKgO\|IhcHK\|	MlLaNVc3ODh\|OU[=
HOS cells	NGPVZZZEgXSxdH;4bYPDqGG\|c3H5		NIjG[4w4OiCq	MYDDfZRwfG:6aXPpeJkh[WejaX7zeEBJV1NiY3XscJMh[W[2ZYKgO\|IhcHK\|	MV2xO\|YxQDN7Nh?=
mouse DA-3 cells	MmfhR5l1d3SxeHnjxsBie3OjeR?=	M2nLO\|IxKM7:TR?=	M{LSdlYxKG2rboO=	NFuzNmZEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBFSS1\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBk\WyuII\pZYJqdGm2eTDheEAzOCC3TTDh[pRmeiB4MDDtbY5{KGK7IGjUWEBie3OjeR?=	NV31dnk5OjR7MEC2Olg>
human G361 cells	MkX6R5l1d3SxeHnjxsBie3OjeR?=		NVv4e5BTPzJiaB?=	NHH3[3pEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBIOzZzIHPlcIx{KGGodHXyJFczKGi{cx?=	MVexO\|YxQDN7Nh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-Chk1 / Chk1 / p-ATR / ATR ; PubMed: 26727128 PLoS One After Caco-2 cells were treated with or without 1 μ M daunorubicin, whole cell extracts were collected at 1, 3, 6, 12, 24, and 48 h and immunoblotted for Chk1, p-Chk1, ATR, and p-ATR. β-actin served as the loading control.	26727128
Immunofluorescence	p-Chk1; PubMed: 26727128 PLoS One Caco-2 cells were treated with or without 1 μ M daunorubicin for 48 h, and then fixed and stained with anti-p-Chk1 antibody and DAPI. Images were collected under a fluorescence microscope. Scale bar = 10 μm.	26727128
Growth inhibition assay	Cell viability; PubMed: 30745844 Int J Biol Sci (A) Viability of AML cell lines under different concentrations of Dnr according to the CCK-8 assay. (B) IC50 of AML cell lines calculated according to the result of the CCK-8 assay.	30745844

Protocol

References

[4] Tardi P, et al. Leuk Res, 2009, 33(1), 129-139.

- Collapse

Solubility (25°C)

In vitro	DMSO	100 mg/mL (177.31 mM)
	Water	100 mg/mL (177.31 mM)
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): Saline For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Daunorubicin HCl SDF

Molecular Weight	563.98
Formula	C₂₇H₂₉NO₁₀ . HCl
CAS No.	23541-50-6
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	Daunomycin HCl

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03878927	Recruiting	Drug: CPX-351\|Drug: Gemtuzumab Ozogamicin	Acute Myeloid Leukemia	Weill Medical College of Cornell University\|Jazz Pharmaceuticals\|Pfizer	August 23 2019	Phase 1
NCT03896269	Recruiting	Drug: Liposome-encapsulated Daunorubicin-Cytarabine	Blasts 10-19 Percent of Bone Marrow Nucleated Cells\|Blasts More Than 5 Percent of Bone Marrow Nucleated Cells\|High Risk Chronic Myelomonocytic Leukemia\|Recurrent Chronic Myelomonocytic Leukemia\|Recurrent High Risk Myelodysplastic Syndrome\|Refractory Chronic Myelomonocytic Leukemia\|Refractory High Risk Myelodysplastic Syndrome	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	May 14 2019	Phase 1
NCT02914977	Active not recruiting	Drug: Daunorubicin	Acute Lymphocytic Leukemia\|Acute Myeloid Leukemia	Tara Lin\|University of Kansas Medical Center	November 2016	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Topoisomerase Signaling Pathway Map

Related Topoisomerase Products

SCR7 ^New

SCR7 is a specific DNA Ligase IV inhibitor, which blocks nonhomologous end-joining (NHEJ). It increases the efficiency of HDR-mediated genome editing up to 19-fold using CRISPR/Cas9 in mammalian cells and mouse embryos.
Blasticidin S HCl ^New

Blasticidin S HCl is a nucleoside antibiotic isolated from Stretomyces girseochromogenes, and acts as a DNA and protein synthesis inhibitor, used to select transfected cells carrying bsr or BSD resistance genes.
LMK-235 ^New

LMK-235 is a selective inhibitor of HDAC4 and HDAC5 with IC50 of 11.9 nM and 4.2 nM, respectively.
Doxorubicin (Adriamycin) HCl

Doxorubicin (Adriamycin) HCl is an antibiotic agent that inhibits DNA topoisomerase II and induces DNA damage and apoptosis in tumor cells.
Etoposide

Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.
Camptothecin

Camptothecin is a specific inhibitor of DNA topoisomerase I (Topo I) with IC50 of 0.68 μM in a cell-free assay. Phase 2.
SN-38

SN-38 is an active metabolite of CPT-11, inhibits DNA topoisomerase I, DNA synthesis and causes frequent DNA single-strand breaks.
Topotecan HCl

Topotecan HCl is a topoisomerase I inhibitor for MCF-7 Luc cells and DU-145 Luc cells with IC50 of 13 nM and 2 nM in cell-free assays, respectively.

Features:Topotecan is a water-soluble derivative of camptothecin.
Idarubicin HCl

Idarubicin HCl is a hydrochloride salt form of Idarubicin which is an anthracycline antibiotic and a DNA topoisomerase II (topo II) inhibitor for MCF-7 cells with IC50 of 3.3 ng/mL in a cell-free assay.

Features:Idarubicin is a substrate for CYP450 2D6 and 2C9.

Choose Your Country or Region

By Signaling Pathways

By product type

Daunorubicin HCl

Cited by 25 Publications

Purity & Quality Control

Choose Selective Topoisomerase Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Daunorubicin HCl SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Topoisomerase Signaling Pathway Map

Related Topoisomerase Products

Choose Your Country or Region

By Signaling Pathways

By product type

Daunorubicin HCl

Cited by 25 Publications

Purity & Quality Control

Choose Selective Topoisomerase Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Daunorubicin HCl SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Topoisomerase Signaling Pathway Map

Related Topoisomerase Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)